The Chemours Company (CC)

From the record

The Chemours Company's filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2024-03-19); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-02-29) (its current reports).

From the record

The Chemours Company's 10 filed years say what it did: revenue went from $5.4 billion in fiscal 2016 to $5.8 billion in fiscal 2025, up 0.8% a year; it rose in 5 of 9 years; the deepest fall was 25% from fiscal 2018 to fiscal 2020; net income was positive in 7 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, The Chemours Company's diluted share count shrank about 1.7% a year, and dividends and buybacks returned about 100% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 7 purchases of their own stock on the open market in the year to 2026-10-01, buying about $489 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, The Chemours Company lost about 154 cents for every dollar of shareholders' money, and gross profitability: its products earned about 12 cents per dollar of everything the company owns. Leverage: it owed about 97 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

From the record

The Chemours Company's standing among 15 graded names in its industry family: revenue of $5.8 billion in fiscal 2025 ranks in the top 11% by size; a net margin of -6.6% ranks in the top 43%; revenue growth of -5.3% a year over the last 3 filed years ranks in the top 43% (its annual reports).

From the record

The Chemours Company's leadership, from its insiders' filings and its current reports: the chief executive on the record is Dignam, Denise (Chief Executive Officer, as filed), filing under that title since 2026-03-03, 8 months (bottom 4% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 2.7 years (bottom 14%); 16 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (bottom 4%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

The Chemours Company's room to grow, from the newest filed statements (fiscal 2025): cash of $670 million against debt of $4.1 billion leaves -46.5% of its assets as net cash, bottom 9% of its family; cash from operations less capital spending is 0.9% of revenue (bottom 43%); a gross margin of 15.5% (bottom 19%); research spending of 1.9% of revenue (bottom 23%) (its annual report).

From the record

The Chemours Company's growth drivers, from the filed years to fiscal 2025: revenue grew -5.3% a year over the last three filed years against 0.8% over all 10, slowing (top 37% of its family); the newest year grew 0.4% (bottom 42%); research spending grew -2.9% a year (bottom 39%); capital spending grew -11.5% a year (bottom 42%) (its annual reports). The Chemours Company reported 2 lines of business in fiscal 2025: All at $5.8 billion (99%), Other Non- at $50 million (1%); 1 of 2 grew against the year before (its annual report).

From the record

The Chemours Company's newest year against its own record: revenue of $5.8 billion in fiscal 2025 came in 9.2% above the $5.3 billion its prior three years' pace pointed to (top 46% of its family); net income of $386 million against a prior three-year average of $131 million (bottom 21%); a net margin of -6.6% against 1.8% before (bottom 38%) (its annual reports).